Evidence map›Paper›PMID 28566467›Full record

ReviewBMJ (Clinical research ed.)2017

Diagnosis and management of inflammatory bowel disease in children.

Stephanie B Oliveira, Iona M Monteiro

Open access · greenAbstract readReview
In one paragraph

Review in BMJ (Clinical research ed.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 5 pooled it
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 5 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. A novel diagnostic serum protein signature for pediatric inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2026
    Observational
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Effect of Tissue Eosinophilia on the Disease Outcome of Pediatric With Inflammatory Bowel Disease (IBD).JGH open : an open access journal of gastroenterology and hepatology · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Stephanie B OliveiraCincinnati Children's Hospital Medical Center Ringgold standard institution, Cincinnati, OH, USA.
Iona M MonteiroRutgers New Jersey Medical School Ringgold standard institution - Pediatrics, Newark, NJ 07103-2714, USA monteiim@njms.rutgers.edu.
Cincinnati Children's Hospital Medical Center · USRutgers, The State University of New Jersey · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI MEINZEN-DERR, JAREEN, STRAWN, JEFFREY ROBERT · 2015 to 2024
$37.5M
NCATS NIH HHS UL1 TR001425
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are lifelong conditions that often begin in childhood. The implications of IBD are of particular importance in children because of the potential negative effects on growth, development, psychosocial function, and overall wellbeing. The key management strategy is to achieve sustained control of intestinal inflammation and monitor for potential complications of the disease and side effects of therapies. Overall, the evidence on the management of IBD in children is less extensive than in adults, but good quality multicenter studies and various guidelines and society consensus statements are available. This review summarizes the evidence on the pathophysiology, diagnosis, and approaches to management of children and adolescents with IBD.

Indexed as

Age of OnsetAnti-Bacterial AgentsBiomarkersChildEndoscopy, GastrointestinalEvidence-Based MedicineGastrointestinal AgentsGenetic Predisposition to DiseaseHumansImmunosuppressive AgentsInflammatory Bowel DiseasesAnti-Bacterial AgentsBiomarkersGastrointestinal AgentsImmunosuppressive Agents

Identifiers

PMID28566467
PMCPMC6888256
OpenAlexW2620505337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.